Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall Street ends down sharply; worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Vertiv shares fall on analyst downgrades and options bets
- Stocks slip as dollar heads for weekly loss
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
Insmed (INSM) PT Raised to $43 at Morgan Stanley
May 9, 2024 12:11 PM EDTMorgan Stanley analyst Jeffrey Hung raised the price target on Insmed (NASDAQ: INSM) to $43.00 (from $40.00) while maintaining a Overweight rating.
The analyst comments "Insmed reported 1Q Arikayce sales of $75.5M (consensus: $78M) and reiterated guidance 2024 Arikayce revenue guidance of $340M-360M. The company... More



